Evolution of the Average Target: Sionna Therapeutics, Inc.

Evolution of the Average Target - Sionna Therapeutics, Inc.

Evolution of the Target Price: Sionna Therapeutics, Inc.

Evolution of the Target Price - Sionna Therapeutics, Inc.

Changes in Analyst Recommendations: Sionna Therapeutics, Inc.

0c54d1d.JsHW1vYGKD5zKx2jbwwcviLSYAqTAL1r1t72-raK85Y.T7mf79s-EXBHGVToImR_9HOGImblX_lchJWwpfnflslNtJi9uHxZbDFAVA~f4d871ff617d2f5be3fd4e30971f7fe1
09-15 Wedbush Raises Price Target on Sionna Therapeutics to $6 From $5, Keeps Neutral Rating MT
08-12 Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says MT
08-11 BTIG Downgrades Sionna Therapeutics to Neutral From Buy MT
08-10 Wedbush Downgrades Sionna Therapeutics to Neutral From Outperform, Adjusts PT to $5 From $53 MT
08-04 Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says MT
05-05 Wedbush Initiates Sionna Therapeutics at Outperform With $53 Price Target MT
12-23 LifeSci Capital Initiates Coverage on Sionna Therapeutics With Outperform Rating, $60 Price Target MT
12-04 Sionna Therapeutics Valuation Topping $2 Billion Is 'Too Optimistic', RBC Says MT
12-01 Sionna Therapeutics Shares Lower After RBC Downgrade MT
12-01 RBC Downgrades Sionna Therapeutics to Underperform From Sector Perform, Keeps $24 Price Target, Speculative Risk MT
11-19 BTIG Research Initiates Coverage on Sionna Therapeutics With Buy Rating, $50 Price Target MT
25-10-21 Sionna Therapeutics, Inc. Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis CI
25-09-09 JonesTrading Initiates Sionna Therapeutics at Buy With $46 Price Target MT
25-09-03 Raymond James Initiates Sionna Therapeutics at Strong Buy MT
25-09-03 RBC Capital Initiates Sionna Therapeutics at Sector Perform With $22 Price Target MT
25-03-04 Guggenheim Initiates Sionna Therapeutics at Buy With $45 Price Target MT
25-03-04 Stifel Initiates Sionna Therapeutics at Buy With $32 Price Target MT
25-03-04 TD Cowen Initiates Sionna Therapeutics at Buy MT
25-02-07 Top Midday Gainers MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+442.64%
+42.48%
+24.46%
+8.88%
+15.87%
+17.86%
+35.3%
+1.94%
+41.27%
+72.28%
Average +70.30%
Weighted average by Cap. +27.26%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
3.870USD
Average target price
21.00USD
Spread / Average Target
+442.64%
High Price Target
63.00USD
Spread / Highest target
+1,527.91%
Low Price Target
5.000USD
Spread / Lowest Target
+29.20%

Analyst Consensus Detail

Analyst consensus - Sionna Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Sionna Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Sionna Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SION Stock
  4. Consensus Sionna Therapeutics, Inc.